Ivan Kairatov stands at the crossroads of a historic transformation in medicine, having spent years navigating the high-stakes world of biopharmaceutical research and development. As an expert with deep roots in both the technical and innovative corridors of the industry, he has witnessed the slow,
The persistent challenge of treating metastatic castration-resistant prostate cancer has long centered on the tumor’s ability to remain invisible to the body’s natural immune defenses while resisting standard therapeutic interventions. A groundbreaking preclinical study led by researchers at Weill
The cardiovascular research community stood in stunned silence this week as a once-heralded clinical champion stumbled at the very finish line of its long journey toward regulatory approval. Shares of Ionis Pharmaceuticals plummeted by 21% in early trading, while AstraZeneca faced an 8% drop,
The relentless march of Huntington’s disease continues to challenge the limits of modern medicine, functioning as a genetic ticking clock that remains largely unstopped despite decades of intensive research. This genetic disorder represents one of the most daunting frontiers in neurology because no
The global battle against tuberculosis has entered a decisive new phase as researchers leverage advanced artificial intelligence to compress decades of traditional pharmaceutical development into a matter of months. Despite being a preventable and curable disease, tuberculosis continues to claim
For more than a century, neurologists have known that the cognitive decay associated with multiple sclerosis stems from damage to the brain’s gray matter, yet these vital areas remained stubbornly invisible on conventional MRI scans until the arrival of sophisticated computational models. The
